ACER3

Across TCGA pan-cancer cohorts, ACER3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ACER3 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ACER3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACER3 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BRCA and BLCA are the cancer types where ACER3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.145	0.579	<.001	27	view →
BLCA	DFS	Median	II,III,IV	1.000	0.607	.028	8	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ACER3–BRCA (OS)

Open the BRCA breakdown →